Regenerative Cell Therapies for Neurodegenerative Diseases
NeuroGenesis is a clinical-stage biotechnology company.
We are advancing innovative cell therapies via our propriety NEURALyzed CELL™ platform to combat neurodegenerative diseases.
Platform
NeuroGenesis NEURALyzed CELL™ proprietary platform enables the neuralization of the
patient’s own stem cells via a highly innovative protocol that focuses on maximizing their
immunomodulation potential, neuronal protection and regenerative capabilities. These cells are
then delivered via an injection into the spinal canal, so that it reaches the cerebrospinal fluid (CSF).
Milestones
Hadassah researchers-initiated Phase I/II
(MS & ALS – 34 Patients)
2005
2010
Published results of Phase I/II
Published Long term Study results (MS – 28 Patients)
2012
2015
Initiated Phase IIA – Progressive MS (48 Patients)
Initiated compassionate treatments (MS , ALS)
Received EU patent
Company established - License from Hadasit & Seed capital
Phase IIB - Unprecedented Interim Results
2018
2019
Publish Phase IIB results – ECTRIMS 2019 Conference
Science
NG-01-MS has been manufactured for treating MS & ALS patients for over 15 years. Trials were investigator initiated and regulated by the Israeli Mistry of Health and local IRB. NeuroGenesis was founded to clinically develop this product.
NG-1 is the company’s lead product. The intended indication of NG-1 is for the treatment of progressive Multiple Sclerosis.
NG-1 has neuroprotective and neuro-regenerative properties. NG-1 can prevent neurons and oligodendrocytes from apoptosis via the release of trophic and anti-apoptotic molecules (NGF, BDNF, and others), and have anti-proliferative effects on microglial cells and astrocytes, resulting in the induction of a neuroprotective microenvironment.
NG-1 also promotes the proliferation and maturation of local neural precursor cells, leading to their differentiation into mature neurons and oligodendrocyte.